Jiangsu Keppra Pharmaceutical

Jiangsu Carephar Pharmaceutical is an innovative Chinese pharmaceutical company specializing in the development and commercialization of therapies for digestive, cardiovascular, and cerebrovascular diseases. The company's flagship product, Keverprazan (Keprasen), is a novel potassium-competitive acid blocker (P-CAB) approved in China for the treatment of duodenal ulcers and other gastric acid-related conditions. Carephar maintains a robust pipeline of small molecule candidates and traditional Chinese medicines, supported by a full industrial chain that includes R&D centers and manufacturing facilities in Nanjing and other parts of Jiangsu. The company has established strategic partnerships with major players like Fosun Pharma for the global commercialization of its lead assets.